NF-κB inhibitors in treatment and prevention of lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Aberrant Nuclear Factor-kappa B (NF-κB) signaling is implicated in various human malignancies, promoting tumorigenesis and cancer survival.
• Constitutive NF-κB expression is observed in solid tumors like lung, pancreatic, breast, and prostate cancers.
• NF-κB signaling plays a crucial role in the progression of several cancers, especially lung tumorigenesis.

Purpose of the Study:

• To explore the role of NF-κB signaling in cancer progression, with a focus on lung cancer.
• To review the development and clinical applications of NF-κB antagonists.
• To highlight the potential of NF-κB inhibition as a therapeutic strategy for lung cancer.

Main Methods:

• Review of existing literature on NF-κB signaling pathways in cancer.
• Analysis of research on NF-κB antagonists and their mechanisms of action, particularly IκB kinase (IKK) beta suppression.
• Examination of clinical trial data for NF-κB inhibitors in lung cancer treatment.

Main Results:

• NF-κB inhibitors are under clinical trials for lung cancer, including small-molecule inhibitors and monoclonal antibodies.
• Combinatorial therapies involving NF-κB inhibition show promise in clinical investigations.
• Suppression of IκB kinase (IKK) beta activity is a common approach for NF-κB antagonism.

Conclusions:

• NF-κB signaling is a critical target for cancer drug development.
• NF-κB antagonists, especially for lung cancer, are progressing through clinical trials with promising preliminary results.
• Targeting NF-κB, particularly through IKK inhibition and combinatorial therapies, offers a viable therapeutic avenue for various cancers, notably lung cancer.